Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) - Total Liabilities
Based on the latest financial reports, Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) has total liabilities worth TL303.09 Million TRY (≈ $6.79 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EGEPO cash generation efficiency to assess how effectively this company generates cash.
Nasmed Ozel Saglik Hizmetleri Ticaret AS - Total Liabilities Trend (2019–2024)
This chart illustrates how Nasmed Ozel Saglik Hizmetleri Ticaret AS's total liabilities have evolved over time, based on quarterly financial data. Check Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Nasmed Ozel Saglik Hizmetleri Ticaret AS Competitors by Total Liabilities
The table below lists competitors of Nasmed Ozel Saglik Hizmetleri Ticaret AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pitanium Ltd
NASDAQ:PTNM
|
USA | $19.87 Million |
|
Magni Tech Industries Bhd
KLSE:7087
|
Malaysia | RM119.97 Million |
|
Principal Capital Public Company Limited
BK:PRINC
|
Thailand | ฿5.47 Billion |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
USA | $122.58 Million |
|
Rishabh Instruments Limited
NSE:RISHABH
|
India | Rs2.67 Billion |
|
Mosel Vitelic Inc
TW:2342
|
Taiwan | NT$831.38 Million |
|
OraSure Technologies Inc
NASDAQ:OSUR
|
USA | $62.34 Million |
|
Triplepoint Venture Growth BDC Corp
NYSE:TPVG
|
USA | $486.03 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Nasmed Ozel Saglik Hizmetleri Ticaret AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Nasmed Ozel Saglik Hizmetleri Ticaret AS.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nasmed Ozel Saglik Hizmetleri Ticaret AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nasmed Ozel Saglik Hizmetleri Ticaret AS (2019–2024)
The table below shows the annual total liabilities of Nasmed Ozel Saglik Hizmetleri Ticaret AS from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | TL303.09 Million ≈ $6.79 Million |
-26.08% |
| 2023-12-31 | TL410.01 Million ≈ $9.18 Million |
+128.87% |
| 2022-12-31 | TL179.14 Million ≈ $4.01 Million |
+83.27% |
| 2021-12-31 | TL97.75 Million ≈ $2.19 Million |
+10.05% |
| 2020-12-31 | TL88.82 Million ≈ $1.99 Million |
+31.57% |
| 2019-12-31 | TL67.51 Million ≈ $1.51 Million |
-- |
About Nasmed Ozel Saglik Hizmetleri Ticaret AS
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi provides healthcare services in Turkey. The company's medical units include oral and dental health; anesthesiology and reanimation; nutrition and diet; brain and nerve surgery; childhood diseases; dermatology; endocrinology and metabolic diseases; infectious diseases and clinical microbiology; aesthetic, plastic, and reconstructive surgery; hom… Read more